Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution

Luo, Bangwei; Wang, Jinsong; Liu, Zongwei; Shen, Zhaohua; Shi, Rongchen; Liu, Yuqi; Liu, Yu; Jiang, Man; Wu, Yuzhang; Zhang, Zhiren

doi:10.1038/ncomms12177

Cited by 60 publications

(59 citation statements)

References 61 publications

(112 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In self-limited peritoneal inflammation mice, EPO concentration in peritoneal fluid appeared bimodal, corresponding with the infiltration of neutrophils and macrophages accompanied with hypoxia caused by respiratory burst 32 . In contrast, the lack of detectable EPO in situ or the macrophage-specific EPOR knockout mice yielded chronic inflammation 32 . Meanwhile, apoptotic cells released the "find me" signal sphingosine 1phosphate (S1P), which specifically binds to S1P receptor 1 (S1PR 1 ) and enhances the expressions of HIF-1α and EPO in macrophages.…”

Section: Innate Immune System Macrophagementioning

confidence: 99%

Erythropoietin and its derivatives: from tissue protection to immune regulation

et al. 2020

View full text Add to dashboard Cite

Erythropoietin (EPO) is an evolutionarily conserved hormone well documented for its erythropoietic role via binding the homodimeric EPO receptor (EPOR) 2. In past decades, evidence has proved that EPO acts far beyond erythropoiesis. By binding the tissue-protective receptor (TPR), EPO suppresses proinflammatory cytokines, protects cells from apoptosis and promotes wound healing. Very recently, new data revealed that TPR is widely expressed on a variety of immune cells, and EPO could directly modulate their activation, differentiation and function. Notably, nonerythropoietic EPO derivatives, which mimic the structure of helix B within EPO, specifically bind TPR and show great potency in tissue protection and immune regulation. These small peptides prevent the cardiovascular side effects of EPO and are promising as clinical drugs. This review briefly introduces the receptors and tissue-protective effects of EPO and its derivatives and highlights their immunomodulatory functions and application prospects.

show abstract

Section: Innate Immune System Macrophagementioning

confidence: 99%

Erythropoietin and its derivatives: from tissue protection to immune regulation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In human macrophages, miRNA‐181b regulates ALX/formyl‐peptide receptor (FPR)‐2 receptor‐evoked resolution responses (117). Erythropoietin promotes resolution, shortening the resolution interval in vivo in mice (118), and several candidate proresolver proteins are identified (27). Endogenous gases, such as H 2 S and CO, have a role in resolution.…”

Section: New Mediators and Pharmacologic Agents Targeting Resolutionmentioning

confidence: 99%

Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms

2017

View full text Add to dashboard Cite

Practitioners of ancient societies from the time of Hippocrates and earlier recognized and treated the signs of inflammation, heat, redness, swelling, and pain with agents that block or inhibit proinflammatory chemical mediators. More selective drugs are available today, but this therapeutic concept has not changed. Because the acute inflammatory response is host protective to contain foreign invaders, much of today's pharmacopeia can cause serious unwanted side effects, such as immune suppression. Uncontrolled inflammation is now considered pathophysiologic and is associated with many widely occurring diseases such as cardiovascular disease, neurodegenerative diseases, diabetes, obesity, and asthma, as well as classic inflammatory diseases (, arthritis and periodontal diseases). The inflammatory response, when self-limited, produces a superfamily of chemical mediators that stimulate resolution of the response. Specialized proresolving mediators (SPMs), identified in recent years, are endogenous mediators that include the n-3-derived families resolvins, protectins, and maresins, as well as arachidonic acid-derived (n-6) lipoxins, which promote resolution of inflammation, clearance of microbes, reduction of pain, and promotion of tissue regeneration novel mechanisms. Aspirin and statins have a positive impact on these resolution pathways, producing epimeric forms of specific SPMs, whereas other drugs can disrupt timely resolution. In this article, evidence from recent human and preclinical animal studies is reviewed, indicating that SPMs are physiologic mediators and pharmacologic agonists that stimulate resolution of inflammation and infection. The findings suggest that it is time to challenge current treatment practices-namely, using inhibitors and antagonists alone-and to develop immunoresolvents as agonists to test resolution pharmacology and their role in catabasis for their therapeutic potential.-Serhan, C. N. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms.

show abstract

“…In addition, a number of candidate proresolver proteins were identified (Bannenberg et al, 2005). More recently, erythropoietin was shown to promote resolution, shortening the resolution interval in vivo in mice (Luo et al, 2016). Novel hybrid compounds of cyclin-dependent kinase inhibitors (CDK i ) and nitric oxide (NO), such as NO-releasing R -roscovitine hybrid derivatives, possess pro-resolution actions (Montanaro et al, 2013), giving promise for new therapeutics as pro-resolving agents.…”

Section: Resolution Pharmacology: New Mediators and Pharmacologic Agementioning

confidence: 99%

Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors

Chiang

Serhan

2017

Molecular Aspects of Medicine

258

232

View full text Add to dashboard Cite

The acute inflammatory response is host protective to contain foreign invaders. Many of today’s pharmacopeia that block pro-inflammatory chemical mediators can cause serious unwanted side effects such as immune suppression. Uncontrolled inflammation is now considered a pathophysiologic basis associated with, many widely occurring diseases such as cardiovascular disease, neurodegenerative diseases, diabetes, obesity and asthma, as well as the classic inflammatory diseases, e.g. arthritis, periodontal diseases. The inflammatory response is designated to be a self-limited process that produces a superfamily of chemical mediators that stimulate resolution of inflammatory responses. Specialized proresolving mediators (SPM) uncovered in recent years are endogenous mediators that include omega-3-derived families resolvins, protectins and maresins, as well as arachidonic acid-derived (n-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via novel mechanisms. Here, we review recent evidence from human and preclinical animal studies, together with the structural and functional elucidation of SPM indicating the SPM as physiologic mediators and pharmacologic agonists that stimulate resolution of inflammation and infection. These results suggest that it is time to develop immunoresolvents as agonists for testing resolution pharmacology in nutrition and health as well as in human diseases and during surgery.

show abstract

Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution

Cited by 60 publications

References 61 publications

Erythropoietin and its derivatives: from tissue protection to immune regulation

Erythropoietin and its derivatives: from tissue protection to immune regulation

Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms

Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors

Contact Info

Product

Resources

About